|
Based on recent recommendations of the International Cancer of the Pancreas (CAPS) Consortium, patients with PJS are eligible for pancreatic surveillance in the framework of a study or registry, irrespective of patients’ family history of pancreatic cancer (PDAC), because of an estimated lifetime risk to develop PDAC of 11–55%. Level of evidence: moderate/low Strength of recommendation: strong |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.